Mereo BioPharma (MREO) Net Income towards Common Stockholders (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$6.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 47.86% year-over-year to -$6.7 million in Q1 2026; TTM through Mar 2026 was -$46.1 million, a 20.55% increase from a year earlier, with the FY2025 full-year figure at -$52.3 million, up 3.37% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$6.7 million, up from -$17.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for MREO reached as high as -$1.8 million in Q2 2023 and fell as low as -$17.9 million in Q4 2024.
• Historically, Net Income towards Common Stockholders has averaged -$11.1 million across 4 years, with a median of -$12.1 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders tumbled 599.89% in 2024 and jumped 53.18% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$10.2 million in 2023, then sank by 76.04% to -$17.9 million in 2024, then rose by 0.8% to -$17.8 million in 2025, then soared by 62.18% to -$6.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$6.7 million in Q1 2026, -$17.8 million in Q4 2025, and -$7.0 million in Q3 2025.